Non-Alcoholic Steatohepatitis Biomarkers Market Research Reveals Strong 22% CAGR Outlook Through 2030

The non-alcoholic steatohepatitis (NASH) biomarkers market is gaining significant traction as advancements in medical technology and personalized healthcare continue to evolve. With growing interest in non-invasive diagnostic methods and biomarker-driven clinical research, this sector is set to experience remarkable growth. Below, we explore the current market size, influential factors, key players, emerging trends, and segmentation details shaping this dynamic market.

Forecasted Market Size Expansion in the Non-Alcoholic Steatohepatitis Biomarkers Market
The market for non-alcoholic steatohepatitis biomarkers is projected to witness substantial growth, reaching a value of $4.6 billion by the year 2030. This represents a robust compound annual growth rate (CAGR) of 22.0%. The anticipated expansion is driven by various factors, such as increasing investments focused on precision hepatology and a surge in demand for non-invasive diagnostic tools. Furthermore, the growing number of biomarker-based clinical trials, rising adoption of personalized medicine, and heightened attention to managing diseases at early stages all contribute to this upward trend. Key market developments expected during this period include the rise of non-invasive biomarker diagnostics, the prevalent use of serum-based NASH biomarkers, increasing incorporation of artificial intelligence (AI) in biomarker evaluation, growth in companion diagnostics for drug development, and a stronger focus on early disease identification.

Download a free sample of the Non-Alcoholic Steatohepatitis Biomarkers market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Critical Drivers Impacting Growth in the Non-Alcoholic Steatohepatitis Biomarkers Market
One major factor fueling market growth is the rising investment in precision hepatology. This area emphasizes tailored treatment strategies based on individual patient profiles, thereby increasing the effectiveness of NASH management and diagnostics.
Additionally, there is an escalating demand for non-invasive diagnostic tools. These methods provide safer, quicker, and more patient-friendly alternatives compared to traditional invasive procedures like biopsies, encouraging wider acceptance and application of biomarker technologies.

Top Companies Leading the Non-Alcoholic Steatohepatitis Biomarkers Market
The industry is dominated by numerous influential companies, including Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, and NGM Biopharmaceuticals Inc. Other key players include Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, and Metacrine.
In a notable development, November 2023 saw Alimentiv Inc., a Canadian clinical research organization specializing in precision medicine and biomarkers, partner with AcelaBio Inc. and PharmaNest Inc. to advance AI-powered digital pathology solutions for NASH and metabolic dysfunction-associated steatohepatitis (MASH) clinical trials. This collaboration aims to integrate high-throughput pathology, spatial transcriptomics, and sophisticated AI biomarker quantification. AcelaBio Inc. is a US-based clinical lab accredited by the College of American Pathologists (CAP), while PharmaNest Inc. specializes in digital pathology and AI-driven quantitative biomarker analysis.

View the full Non-Alcoholic Steatohepatitis Biomarkers market report:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Emerging Trends Highlighted in the Non-Alcoholic Steatohepatitis Biomarkers Market
Market leaders are increasingly adopting advanced biomarker platform technologies, such as multi-analyte fibrosis-scoring assays, to improve non-invasive evaluation of disease progression and enhance patient risk stratification. These assays analyze multiple fibrosis-related proteins in a single blood draw, applying algorithms to calculate scores that reflect disease severity and help detect advanced fibrosis.
For example, Siemens Healthineers, a Germany-based medical technology firm, received breakthrough device designation from the US Food and Drug Administration in July 2023 for its Enhanced Liver Fibrosis Test. This test is a multi-analyte fibrosis-scoring assay designed to support the detection of advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease. By providing a numerical score based on three direct fibrosis biomarkers, it facilitates earlier clinical assessment and reduces dependence on invasive biopsies.

Segmentation Overview of the Non-Alcoholic Steatohepatitis Biomarkers Market
This report divides the non-alcoholic steatohepatitis biomarkers market into several primary segments:
1) By Type, featuring categories such as Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, and Other Types.
2) By Technology, which includes Enzyme-Linked Immunosorbent Assay (ELISA), Mass Spectrometry, Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and other technologies.
3) By End Use, covering Research Institutes and Academics, Diagnostic Centers, Pharmaceutical Companies and Contract Research Organizations (CROs), Hospitals and Clinics, as well as other applications.

Further subcategories specify notable biomarkers such as:
- Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
- Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
- Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
- Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
- Other Types: Metabolomic, Genetic, and Inflammatory Biomarkers

Together, these classifications provide a detailed framework for understanding the various technologies and applications driving the growth of the NASH biomarkers market.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.